Biolinq lands $58m to advance wearable metabolic health technology

Written by

Danny Sullivan

Health tech company Biolinq has secured $58 million in new funding to advance its biosensor technology for enhancing metabolic health. The San Diego-based company’s first device is a wearable continuous glucose monitoring patch that measures blood sugar using tiny microneedles, without requiring a separate device to report results.

Utilizing an array of miniature electrochemical sensors to monitor glucose levels from just beneath the skin’s surface, Biolinq’s wearable patch integrates glucose data with a user’s activity levels in a single device. Placed on the upper forearm, the patch features a display that notifies users when glucose levels are within target ranges or if they exceed healthy thresholds.

“Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding,” said Biolinq CEO Rich Yang. Read more at: https://longevity.technology/news/biolinq-lands-58m-to-advance-wearable-metabolic-health-technology/

‍

Other news

Mass Device

June 2, 2024

Biolinq raises $58M to support intradermal glucose sensor

Biolinq announced today that it completed $58 million financing to support the progression of its proprietary intradermal glucose sensor. Alpha Wave Ventures led the funding round. Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures also participated.

Biolinq: Less pain, $58m gain for tiny glucose sensor

In a sweet indication of an improving capital market for med-tech companies, Biolinq Inc. landed $58 million in bridge financing to support completion of the U.S. pivotal trial of its intradermal glucose sensor and submission to the U.S. FDA.

Written by

Anette Boyle

Medical Device Network

June 2, 2024

Biolinq raises $58m for glucose microsensor pivotal trial

Biolinq is eying an FDA application this year, according to CEO Richard Yang. “The pivotal study started in March 2024 and we plan to file for US Food and Drug Administration (FDA) clearance this year.” said Yang.

Written by

Robert Barrie